Peripheral immune profile and neutrophil-to-lymphocyte ratio in Progressive Supranuclear Palsy
Objective: This study aimed to evaluate the peripheral immune profile in patients with Progressive Supranuclear Palsy (PSP) compared with patients with Parkinson’s disease (PD) and…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Transcriptome analysis of proteasome and inflammation in the substantia nigra of Parkinson’s disease patients: the GEO database.
Objective: In this study, we analyzed transcriptome data regarding protein degradation pathways and inflammation sourced from GEO database. Background: Parkinson's disease (PD) is the second…The links between frontal deficits and levels of inflammatory parameters in Progressive Supranuclear Palsy
Objective: The goal of the research was to verify the possible association between the levels of inflammatory factors and frontal deficits in Progressive Supranuclear Palsy…Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: This study aimed to explore cellular inflammatory and autophagic mediators in neuronal exosomes of PD and PSP. Background: Parkinson’s disease (PD) is a common…Prokineticin-2 is highly expressed in colonic mucosa of early Parkinson’s disease patients
Objective: To investigate the expression of PK2 in colonic biopsies of PD patients. Background: Neuroinflammation is emerging as a key factor involved in the pathophysiology…Peripheral inflammation severity in differential diagnosis of progressive supranuclear palsy and multiple system atrophy – usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and neutrophil-to-high-density lipoprotein-cholesterol ratio
Objective: Assessment of the possible differences in peripheral inflammation severity between progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) with the use of three…Bright Light Therapy: A Novel Non-Pharmacological Approach to Parkinson’s Disease
Objective: To assess the effectiveness of Bright Light Therapy (BLT) in ameliorating symptoms and neuropathology in an α-synuclein preformed fibril (α-syn PFF) induced Parkinson’s disease…Study of Cytokine profile in a Tunisian Parkinson’s Disease cohort
Objective: We aim to study the relationship between clinical features in patients with Parkinson’s disease (PD) and their IL-6 and IL-1β serum levels. Background: According…Cytokine Profiles as Biomarkers for Neurodegenerative Diseases: An inflammatory study on Parkinson’s Disease and Tauopathies
Objective: To investigate the diagnostic and prognostic value of cytokine profiles in cerebrospinal fluid (CSF) and serum of patients with Parkinson's Disease (PD), Progressive Supranuclear…
- 1
- 2
- 3
- …
- 22
- Next Page »